Chennai-based drug maker, Orchid Pharma, has signed a technology transfer agreement with a multinational biotechnology company, for its 7AC...

Hyderabad, Dec 9- Prestige BioPharma Ltd, a Singapore-based firm and Dr. Reddy's Laboratories Ltd., on Thursday announced that the two comp...

Germany’s Bayer will pay $2 billion upfront and up to an additional $2 billion in milestone payments contingent on development achievements...

According to the US health regulator, USFDA, 'orphan drug' is a drug or biologic that is used for the prevention, diagnosis, or treatment o...

Biocon, the Bengaluru-headquartered bio-pharma firm and the parent company for Biocon Biologics, has has been recognised as the ASIA IP ELI...

Torrent Pharma said it plans further investments to expand the BPI facilities, including its research and development (R&D) capabilities, a...

The company said its board has appointed Gopal Daptari as additional independent director with immediate effect up to the conclusion of the...

This is the first pact the city-based clinical research the company has inked after it got involved in regulatory issues with European Medi...

The only investment which has not yet borne fruit for Shanghvi is his stake in BioLight Israeli Life Sciences Investments, which is listed ...

Gland Pharma makes and markets specialised injectable formulations for generic versions of drugs, it also manufactures a limited quantity o...

US-based bio-pharmaceutical company Gilead Sciences on Tuesday entered into new licensing pacts with four Indian firms.

Drug firm Strides Arcolab said it has entered into an agreement with Bio-XCell Sdn Bhd for establishing a facility in Malaysia.

India's biotech industry bounced to high growth in fiscal 2009-10 to post revenues of $4 billion, a whopping 52 per cent over the previous ...

The US healthcare bill, which has been passed by the US House of Representatives and is awaiting nod from the Senate, holds a lot of promis...

Pharmaceutical firm Cadila Healthcare will set up a bio-technology plant here with an investment of Rs 25 crore for manufacturing biosimila...

Malladi Drugs and Pharmaceutical Ltd will invest up to USD 300 million over the next three to five years to set up its global "one-stop sho...

At a time when the US generic drugs market is reeling under price competition, a recent move by the US government to accelerate approvals o...